Haitao Chen1, Yueying Li2,3, Shu-Yuan Xiao4,5,6, Jianchun Guo7,8. 1. Department of Orthopedic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. 2. Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. 3. Wuhan University Center for Pathology and Molecular Diagnostics, Wuhan, 430071, China. 4. Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. syxiao@whu.edu.cn. 5. Wuhan University Center for Pathology and Molecular Diagnostics, Wuhan, 430071, China. syxiao@whu.edu.cn. 6. Department of Pathology, University of Chicago Medicine, Chicago, IL, USA. syxiao@whu.edu.cn. 7. Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. spring0324@126.com. 8. Wuhan University Center for Pathology and Molecular Diagnostics, Wuhan, 430071, China. spring0324@126.com.
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) is a common malignant tumor with a poor prognosis. We aimed to identify a new prognostic model of HCC based on differentially expressed (DE) immune genes. METHODS: The DE immune genes were identified based on an analysis of 374 cases of HCC and 50 adjacent non-tumor specimens from the Cancer Genome Atlas (TCGA) database. Univariate Cox analysis, Lasso regression, and multivariate Cox analysis were used to construct the model based on the training group. Survival analysis and the receiver operating characteristic (ROC) curves were used to evaluate model performance. The testing group and the entire group were subsequently used for validation of the model. RESULTS: A five-immune gene model consisted of HSPA4, ISG20L2, NDRG1, EGF, and IL17D was identified. Based on the model, the overall survival was significantly different between the high-risk and low-risk groups (P = 7.953e-06). The AUCs for the model at 1- and 3-year were 0.849 and 0.74, respectively. The reliability of the model was confirmed using the validation groups. The risk score was identified as an independent prognostic parameter and closely related to the content of immune cells from human HCC specimens. CONCLUSION: We identified a five-immune gene model that can be used as an independent prognostic marker for HCC.
BACKGROUND:Hepatocellular carcinoma (HCC) is a common malignant tumor with a poor prognosis. We aimed to identify a new prognostic model of HCC based on differentially expressed (DE) immune genes. METHODS: The DE immune genes were identified based on an analysis of 374 cases of HCC and 50 adjacent non-tumor specimens from the Cancer Genome Atlas (TCGA) database. Univariate Cox analysis, Lasso regression, and multivariate Cox analysis were used to construct the model based on the training group. Survival analysis and the receiver operating characteristic (ROC) curves were used to evaluate model performance. The testing group and the entire group were subsequently used for validation of the model. RESULTS: A five-immune gene model consisted of HSPA4, ISG20L2, NDRG1, EGF, and IL17D was identified. Based on the model, the overall survival was significantly different between the high-risk and low-risk groups (P = 7.953e-06). The AUCs for the model at 1- and 3-year were 0.849 and 0.74, respectively. The reliability of the model was confirmed using the validation groups. The risk score was identified as an independent prognostic parameter and closely related to the content of immune cells from humanHCC specimens. CONCLUSION: We identified a five-immune gene model that can be used as an independent prognostic marker for HCC.
Entities:
Keywords:
Hepatocellular carcinoma; Immune gene; Pathology; Prognosis; Risk model
Authors: Lillian L Siu; S Percy Ivy; Erica L Dixon; Amy E Gravell; Steven A Reeves; Gary L Rosner Journal: Clin Cancer Res Date: 2017-09-01 Impact factor: 12.531
Authors: David Agdashian; Mei ElGindi; Changqing Xie; Milan Sandhu; Drew Pratt; David E Kleiner; William D Figg; Julie A Rytlewski; Catherine Sanders; Erik C Yusko; Bradford Wood; David Venzon; Gagandeep Brar; Austin G Duffy; Tim F Greten; Firouzeh Korangy Journal: Cancer Immunol Immunother Date: 2019-01-28 Impact factor: 6.968
Authors: Kathleen A Cronin; Andrew J Lake; Susan Scott; Recinda L Sherman; Anne-Michelle Noone; Nadia Howlader; S Jane Henley; Robert N Anderson; Albert U Firth; Jiemin Ma; Betsy A Kohler; Ahmedin Jemal Journal: Cancer Date: 2018-05-22 Impact factor: 6.860